AlloVir, Inc. (NASDAQ:ALVR) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its position in shares of AlloVir, Inc. (NASDAQ:ALVR) by 83.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,055 shares of the company’s stock after selling 287,507 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in AlloVir were worth $46,000 as of its most recent SEC filing.

Separately, Cubist Systematic Strategies LLC grew its stake in AlloVir by 152.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after acquiring an additional 30,072 shares during the period. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

AlloVir Stock Performance

NASDAQ:ALVR opened at $0.40 on Friday. The stock has a market capitalization of $46.69 million, a PE ratio of -0.46 and a beta of 0.59. AlloVir, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $2.36. The company has a fifty day moving average of $0.66 and a two-hundred day moving average of $0.73.

AlloVir (NASDAQ:ALVR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10.

AlloVir Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.